DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $46.00 price target on the stock.
Ashland, Bitdeer, and More Stocks See Action From Activist Investors [Yahoo! Finance]
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Form 4 Dianthus Therapeutics, For: Dec 04 Filed by: Savitz Ryan
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
Form SCHEDULE 13D/A Dianthus Therapeutics, Filed by: Fairmount Funds Management LLC
Form SCHEDULE 13D/A Dianthus Therapeutics, Filed by: Avidity Partners Management LP
Form 4 Dianthus Therapeutics, For: Nov 13 Filed by: Randhawa Simrat
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.